Clinical Trials Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2014; 20(25): 8229-8236
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8229
Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin
Ya-Jie Zhang, A-Jian Li, Yi Han, Lu Yin, Mou-Bin Lin
Ya-Jie Zhang, A-Jian Li, Yi Han, Lu Yin, Mou-Bin Lin, Department of General Surgery, RuiJin Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
Author contributions: Zhang YJ designed the research; Zhang YJ, Li AJ, Han Y and Lin MB performed the research and analyzed the data; Zhang YJ wrote the paper.
Supported by National Natural Science Foundation of China, No. 81272480/H1609
Correspondence to: Mou-Bin Lin, PhD, Department of General Surgery, RuiJin Hospital Affiliated Shanghai Jiaotong University School of Medicine, No. 197, Ruijin No. 2 Road, Shanghai 200025, China. lmbin@hotmail.com
Telephone: +86-21-64370045 Fax: +86-21-64333548
Received: September 16, 2013
Revised: March 9, 2014
Accepted: April 15, 2014
Published online: July 7, 2014
Core Tip

Core tip: The chemoresistance to oxaliplatin is a major problem in the treatment of colorectal cancer (CRC). In this study, a lentivirus-mediated shRNA was constructed to investigate the role of Girdin, a potential regulator of chemotherapy sensitivity. We found that Girdin knockdown enhanced chemosensitivity of colorectal cells to oxaliplatin via reduction of TOP2B. This suggested that Girdin is a modulator of CRC chemoresistance and a potential therapeutic target.